ECSP077997A - Moduladores de alquilquinolina y alquilquinazolina cinasa - Google Patents
Moduladores de alquilquinolina y alquilquinazolina cinasaInfo
- Publication number
- ECSP077997A ECSP077997A EC2007007997A ECSP077997A ECSP077997A EC SP077997 A ECSP077997 A EC SP077997A EC 2007007997 A EC2007007997 A EC 2007007997A EC SP077997 A ECSP077997 A EC SP077997A EC SP077997 A ECSP077997 A EC SP077997A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- trkb
- flt3
- kit
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La invención se refiere a compuestos alquinolina y alquinazolina de fórmula I:en donde R1, R2, R3, B, Z, G, Q y X son como se define en la presente, el uso de dichos compuestos como moduladores de proteína tirosina cinasa, particularmente inhibidores de FLT3 y/o c?kit y/o TrkB, el uso de dichos compuestos para reducir o inhibir la actividad cinasa de FLT3 y/o c kit y/o TrkB en una célula o un sujeto, y el uso de dichos compuestos para la prevención o tratamiento en un sujeto de un trastorno proliferante celular y/o trastornos relacionados a FLT3 y/o c kit y/o TrkB; la presente invención se refiere además a composiciones farmacéuticas que comprenden los compuestos de la presente invención y a métodos para el tratamiento de condiciones tales como cánceres y otros trastornos proliferantes celulares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68938405P | 2005-06-10 | 2005-06-10 | |
US73091905P | 2005-10-27 | 2005-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP077997A true ECSP077997A (es) | 2008-01-23 |
Family
ID=37038081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2007007997A ECSP077997A (es) | 2005-06-10 | 2007-12-10 | Moduladores de alquilquinolina y alquilquinazolina cinasa |
Country Status (18)
Country | Link |
---|---|
US (1) | US8071768B2 (es) |
EP (1) | EP1893598A1 (es) |
JP (1) | JP2009501135A (es) |
KR (1) | KR20080028912A (es) |
AR (1) | AR054386A1 (es) |
AU (1) | AU2006257945A1 (es) |
BR (1) | BRPI0611964A2 (es) |
CA (1) | CA2611242A1 (es) |
CR (1) | CR9652A (es) |
EA (1) | EA200800017A1 (es) |
EC (1) | ECSP077997A (es) |
GT (1) | GT200600251A (es) |
IL (1) | IL187692A0 (es) |
NO (1) | NO20080174L (es) |
PE (1) | PE20070014A1 (es) |
TW (1) | TW200716599A (es) |
UY (1) | UY29588A1 (es) |
WO (1) | WO2006135721A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7825244B2 (en) * | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
US8760507B2 (en) * | 2008-08-05 | 2014-06-24 | Inspectron, Inc. | Light pipe for imaging head of video inspection device |
EP2518064A1 (en) * | 2009-12-25 | 2012-10-31 | Mochida Pharmaceutical Co., Ltd. | Novel aryl urea derivative |
PL2621923T3 (pl) | 2010-09-29 | 2017-08-31 | Intervet International B.V. | Związki n-heteroarylu z mostkami cyklicznymi do leczenia chorób pasożytniczych |
KR101924247B1 (ko) | 2011-07-27 | 2019-02-22 | 에이비 사이언스 | 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체 |
LT2922845T (lt) * | 2012-11-20 | 2018-09-10 | Merial, Inc. | Antihelmintiniai junginiai ir kompozicijos ir jų naudojimo būdai |
DK3059227T3 (da) * | 2013-10-16 | 2019-08-26 | Fujifilm Corp | Salt af en nitrogen-holdig heterocyklisk forbindelse eller krystal deraf, farmaceutisk sammensætning og flt3-hæmmer |
JP2016540811A (ja) * | 2013-12-20 | 2016-12-28 | ファイザー・リミテッドPfizer Limited | N−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤 |
EP3215141A4 (en) | 2014-11-05 | 2018-06-06 | Flexus Biosciences, Inc. | Immunoregulatory agents |
UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
JP6412471B2 (ja) * | 2015-07-15 | 2018-10-24 | 富士フイルム株式会社 | 含窒素複素環化合物の製造方法およびその中間体 |
JP7455133B2 (ja) * | 2018-09-27 | 2024-03-25 | シェンチェン チップスクリーン バイオサイエンシズ カンパニー、リミテッド | インドールアミン-2,3-ジオキシゲナーゼ阻害活性を有するキノロン誘導体 |
CA3128085A1 (en) * | 2018-12-21 | 2020-06-25 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Dna-pkcs inhibitors for increasing genome editing efficiency |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3517005A (en) | 1967-10-26 | 1970-06-23 | Pfizer & Co C | Certain 2- and 4-substituted quinazolines |
GB1460389A (en) | 1974-07-25 | 1977-01-06 | Pfizer Ltd | 4-substituted quinazoline cardiac stimulants |
JPS5976082A (ja) | 1982-10-23 | 1984-04-28 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
GB8320958D0 (en) | 1983-08-03 | 1983-09-07 | Pfizer Ltd | Quinazoline cardiac stimulants |
US5300515A (en) | 1991-01-31 | 1994-04-05 | Kyorin Pharmaceutical Co., Ltd. | Carbamic acid derivatives and method for preparing the same |
CA2452130A1 (en) | 1992-03-05 | 1993-09-16 | Francis J. Burrows | Methods and compositions for targeting the vasculature of solid tumors |
US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
AU4952096A (en) | 1995-04-19 | 1996-11-07 | Schneider (Usa) Inc. | Drug release coated stent |
WO1997028118A1 (en) | 1996-02-05 | 1997-08-07 | Hoechst Celanese Corporation | Process for preparing anthranilic acids |
CA2250943A1 (en) | 1996-04-12 | 1997-10-23 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
US5948786A (en) * | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
US5869669A (en) * | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
KR100622323B1 (ko) | 1996-10-01 | 2006-11-30 | 교와 핫꼬 고교 가부시끼가이샤 | 질소-함유헤테로고리화합물 |
US5866562A (en) | 1996-10-25 | 1999-02-02 | Bayer Aktiengesellschaft | Ring-bridged bis-quinolines |
EP1047691A1 (en) | 1997-12-12 | 2000-11-02 | Smithkline Beecham Plc | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
DE19756388A1 (de) | 1997-12-18 | 1999-06-24 | Hoechst Marion Roussel De Gmbh | Substituierte 2-Aryl-4-amino-chinazoline |
GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
EP1230225A2 (en) | 1999-11-01 | 2002-08-14 | Eli Lilly And Company | Pharmaceutically active 4-substituted pyrimidine derivatives |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
AU2001293207A1 (en) | 2000-08-18 | 2002-03-04 | Cor Therapeutics, Inc. | Nitrogenous heterocyclic compounds |
US6956039B2 (en) | 2000-08-18 | 2005-10-18 | Millennium Pharmaceuticals, Inc. | Nitrogenous heterocylic compounds |
US6656942B2 (en) | 2000-10-17 | 2003-12-02 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
BR0116113A (pt) | 2000-12-12 | 2004-08-03 | Neurogen Corp | Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas |
DE10109866A1 (de) | 2001-03-01 | 2002-09-05 | Abbott Gmbh & Co Kg | Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie |
WO2002088107A1 (en) | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
WO2003024969A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
KR20090087139A (ko) | 2001-10-30 | 2009-08-14 | 노파르티스 아게 | Flt3 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체 |
US6686362B2 (en) | 2001-12-27 | 2004-02-03 | Theravance, Inc. | Indolinone derivatives |
PL371486A1 (en) | 2002-02-01 | 2005-06-13 | Astrazeneca Ab | Quinazoline compounds |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
MXPA05000081A (es) | 2002-06-27 | 2005-04-11 | Schering Ag | Quinolinas sustituidas antagonistas del receptor ccr5. |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
PL375447A1 (en) | 2002-08-14 | 2005-11-28 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
AU2003288899B2 (en) | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
EP1566379A4 (en) | 2002-10-29 | 2005-11-09 | Kirin Brewery | QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME |
EP1565187A4 (en) | 2002-11-13 | 2010-02-17 | Novartis Vaccines & Diagnostic | CANCER TREATMENT METHODS AND RELATED METHODS |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
US7326712B2 (en) | 2003-10-14 | 2008-02-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Substituted tricyclic compounds as protein kinase inhibitors |
RU2006121990A (ru) | 2003-11-21 | 2007-12-27 | Эррэй Биофарма Инк. (Us) | Ингибиторы протеинкиназ акт |
US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
-
2006
- 2006-06-06 US US11/422,349 patent/US8071768B2/en active Active
- 2006-06-07 EA EA200800017A patent/EA200800017A1/ru unknown
- 2006-06-07 JP JP2008515954A patent/JP2009501135A/ja not_active Withdrawn
- 2006-06-07 PE PE2006000627A patent/PE20070014A1/es not_active Application Discontinuation
- 2006-06-07 WO PCT/US2006/022414 patent/WO2006135721A1/en active Application Filing
- 2006-06-07 EP EP06772652A patent/EP1893598A1/en not_active Withdrawn
- 2006-06-07 BR BRPI0611964-6A patent/BRPI0611964A2/pt not_active Application Discontinuation
- 2006-06-07 AU AU2006257945A patent/AU2006257945A1/en not_active Abandoned
- 2006-06-07 KR KR1020087000405A patent/KR20080028912A/ko not_active Application Discontinuation
- 2006-06-07 CA CA002611242A patent/CA2611242A1/en not_active Abandoned
- 2006-06-08 GT GT200600251A patent/GT200600251A/es unknown
- 2006-06-08 UY UY29588A patent/UY29588A1/es unknown
- 2006-06-09 AR ARP060102422A patent/AR054386A1/es not_active Application Discontinuation
- 2006-06-09 TW TW095120477A patent/TW200716599A/zh unknown
-
2007
- 2007-11-27 IL IL187692A patent/IL187692A0/en unknown
- 2007-12-10 EC EC2007007997A patent/ECSP077997A/es unknown
-
2008
- 2008-01-09 CR CR9652A patent/CR9652A/es not_active Application Discontinuation
- 2008-01-10 NO NO20080174A patent/NO20080174L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2611242A1 (en) | 2006-12-21 |
GT200600251A (es) | 2007-01-12 |
US20060281772A1 (en) | 2006-12-14 |
EP1893598A1 (en) | 2008-03-05 |
TW200716599A (en) | 2007-05-01 |
IL187692A0 (en) | 2008-08-07 |
KR20080028912A (ko) | 2008-04-02 |
CR9652A (es) | 2008-09-09 |
BRPI0611964A2 (pt) | 2009-01-27 |
UY29588A1 (es) | 2006-10-02 |
US8071768B2 (en) | 2011-12-06 |
NO20080174L (no) | 2008-02-19 |
AR054386A1 (es) | 2007-06-20 |
PE20070014A1 (es) | 2007-03-08 |
JP2009501135A (ja) | 2009-01-15 |
WO2006135721A1 (en) | 2006-12-21 |
AU2006257945A1 (en) | 2006-12-21 |
EA200800017A1 (ru) | 2008-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP077997A (es) | Moduladores de alquilquinolina y alquilquinazolina cinasa | |
NI200700313A (es) | Aminopirimidinas como moduladores de la cinasa . | |
NI200700316A (es) | Aminopirimidinas como moduladores de la cinasa | |
ECSP077998A (es) | Moduladores de cinasa de aminoquinolina y aminoquinazolina | |
NI200700311A (es) | Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3 | |
NI200800179A (es) | Triazolopiridazinas como moduladores de la tirosina cinasa | |
CU20070160A7 (es) | Pirrolopirazoles, inhibidores potentes de quinasa | |
CR10094A (es) | Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa | |
EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
ECSP109953A (es) | Derivados de piridazinona | |
UY28941A1 (es) | Indazoles sustituidos, composiciones que los contienen, procedimiento de preparacion y su uso | |
ECSP099662A (es) | Nuevos Derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida | |
ECSP088561A (es) | Derivados de pirimidinil-aril-urea que son inhibidores de fgf | |
ECSP088152A (es) | 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización | |
EA200901138A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
EA201071224A1 (ru) | Ингибиторы limk2, композиции, содержащие их, и способы их применения | |
ECSP088252A (es) | 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización | |
CR20110082A (es) | Nuevos inhibidores de la proteina tirosina quinasa y receptores vegf-2 y uso farmacéutico de los mismos | |
NI200700312A (es) | Intermediarios útiles en las síntesis de moduladores de la cinasa de alquilquinoleína y alquilquinazolina y métodos de síntesis relacionados. | |
UY29592A1 (es) | Aminopirimidinas como moduladores de quinasas | |
UY29587A1 (es) | Moduladores de aminoquinolina y aminoquinazolina quinasa | |
CR9238A (es) | Pirrolopirazoles, potentes inhibidores de cinasa |